Long-term immunity in young adults after a single dose of inactivated Hepatitis A vaccines

Vaccine

Volumn 24, Issue 20, 2006, Pages 4328-4332

  Orr, Nadav ^a,b   Klement, Eyal ^a   Gillis, David ^c   Sela, Tamar ^a   Kayouf, Raid ^a   Derazne, Estela ^a   Grotto, Itamar ^a,d   Balicer, Ran ^a   Huerta, Michael ^a   Aviram, Lisa ^a   Ambar, Ruhama ^a   Epstein, Yoram ^a   Heled, Yuval ^a   Cohen, Dani ^b  

^a MEDICAL CORPS   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Hepatitis A vaccine; Long term protection; Single dose

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; INACTIVATED VACCINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; FEMALE; HEPATITIS A; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION; VACCINATION REACTION; VOMITING;

ADOLESCENT; ADULT; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; VACCINES, INACTIVATED;

EID: 33646483499     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.010     Document Type: Article

References (16)

1. Clarke P., Kitchin N., and Souverbie F. A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim. Vaccine 19 (2001) 4429-4433
2. Connor B.A., Phair J., Sack D., McEniry D., Hornick D., Banerjee D., et al. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix. Clin Infect Dis 32 (2001) 396-401
3. Zuckerman J.N., Kirkpatrick C.T., and Huang M. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL. U) as a booster following primary immunization with Havrix (1440 EL. U) against hepatitis. Am J Travel Med 5 (1998) 18-22
4. Van Herck K., Beutels P., Van Damme P., Beutels M., Van des Dries J., Briantais P., et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 60 1 (2000) 1-7
5. Van Herck K., Van Damme P., Lievens M., and Stoffel M. Hepatitis A vaccine: evidence of immune memory 12 years after the primary course. J Med Virol 72 2 (2004) 194-196
6. Lee D.J., Meehan R.T., Robinson C., Mabry T.R., and Smith M.L. Immune responsiveness and risk of illness in U.S. Air Force Academy cadets during basic cadet training. Aviat Space Environ Med 6 (1992) 517-523
7. Mackinnon L.T. Chronic exercise training effects on immune function. Med Sci Sports Exerc (2000) S369-S376
8. Iwarson S., Lindh M., and Widerstrom L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med 11 2 (2004) 120-121
9. Landry P., Tremblay S., Darioli R., and Genton B. Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose. Vaccine 19 (2000) 399-402
10. Samandari T., Bell B.P., and Armstrong G.L. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine 22 (2004) 4342-4350
11. Van Damme P., Banatvala J., Fay O., Iwarson O., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: is there a need?. Lancet 362 (2003) 1065-1071
12. Gdalevich M., Grotto I., Mandel Y., Mimouni D., Shemer J., and Ashkenazi I. Hepatitis A antibody prevalence among young adults in Israel-the decline continues. Epidemiol Infect 121 (1998) 477-479
13. Dagan R., Greenberg D., Goldenbertg-Gehtman P., Vidor E., Briantais P., Pinsk V., et al. Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Vaccine 17 (1999) 1919-1925
14. Ashur Y., Adler R., Rowe M., and Shouval D. Comparison of immunogenicity of two hepatitis A vaccines - VAQTA and HAVRIX - in young adults. Vaccine 17 (1999) 2290-2296
15. Bryan J.P., Henry C.H., Hoffman A.G., South-Paul J.E., Smith J.A., and Cruess D. Spieker JM, de Medina M. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 19 (2000) 743-750
16. Mackinnon L.T. Immunity in athletes. Int J Sports Med (1997) S62-S68